--- title: "CAMP4 Highlights Preclinical Progress of SYNGAP1 Therapy" type: "News" locale: "en" url: "https://longbridge.com/en/news/286426973.md" description: "CAMP4 Therapeutics announced preclinical data on May 14, 2026, showing that its candidate CMP-002 improved seizure threshold and reduced severity in a SYNGAP1 mouse model. This supports the company's plan to enter Phase 1/2 clinical trials in late 2026. Analysts rate CAMP stock as a Buy with a $12.00 target, though Spark's AI Analyst gives it a Neutral score due to weak financial performance and mixed technicals. CAMP4 focuses on RNA-targeting therapeutics for genetic diseases, with a current market cap of $233.7M." datetime: "2026-05-14T13:38:14.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286426973.md) - [en](https://longbridge.com/en/news/286426973.md) - [zh-HK](https://longbridge.com/zh-HK/news/286426973.md) --- # CAMP4 Highlights Preclinical Progress of SYNGAP1 Therapy ### Claim 55% Off TipRanks - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks The latest announcement is out from CAMP4 Therapeutics Corporation ( (CAMP) ). On May 14, 2026, CAMP4 Therapeutics reported new preclinical data showing that its lead antisense oligonucleotide candidate, CMP-002, significantly improved seizure threshold and reduced seizure severity in a SYNGAP1 haploinsufficient mouse model using a pentylenetetrazol-induced seizure paradigm. These results, which build on earlier findings of neurodevelopmental benefit and broad brain distribution, reinforce CMP-002’s potential as a disease-modifying therapy for SYNGAP1-related disorder and support the company’s plan to move the program into a Phase 1/2 clinical trial for patients in the second half of 2026, underscoring CAMP4’s strategic push to translate its RNA-regulatory platform into first-in-class treatments for a rare CNS disease with no approved disease-modifying options. The most recent analyst rating on (CAMP) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on CAMP4 Therapeutics Corporation stock, see the CAMP Stock Forecast page. **Spark’s Take on CAMP Stock** According to Spark, TipRanks’ AI Analyst, CAMP is a Neutral. The score is primarily held back by weak financial performance (very small and declining revenue, large ongoing losses, and material cash burn). Technicals are mixed with neutral momentum but price still below key medium-term averages. Offsetting factors include supportive corporate developments, particularly meaningful funding and collaboration progress, and a currently low-leverage balance sheet. To see Spark’s full report on CAMP stock, click here. **More about CAMP4 Therapeutics Corporation** CAMP4 Therapeutics Corporation is a clinical-stage biopharmaceutical company focused on developing regulatory RNA-targeting therapeutics designed to upregulate gene expression and restore healthy protein levels to treat a broad range of genetic diseases. Leveraging its proprietary RAP Platform, CAMP4 designs antisense oligonucleotide drug candidates that target regulatory RNAs associated with haploinsufficient and recessive partial loss-of-function disorders, aiming to deliver disease-modifying benefits across more than 1,200 such conditions. **Average Trading Volume:** 191,993 **Technical Sentiment Signal:** Sell **Current Market Cap:** $233.7M For a thorough assessment of CAMP stock, go to TipRanks’ Stock Analysis page. ### Related Stocks - [CAMP.US](https://longbridge.com/en/quote/CAMP.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) ## Related News & Research - [Pharma giants commit $500B to US amid tariff threat](https://longbridge.com/en/news/289866895.md) - [The wrong prescription for drug affordability](https://longbridge.com/en/news/289929515.md) - [CAMP4 Reports Net Loss Of $18 Mln In Q1; Advances CMP-002 For SYNGAP1-related Disorders](https://longbridge.com/en/news/285745839.md) - [CAMP4 Therapeutics Corporation (CAMP) Receives a New Rating from Chardan Capital](https://longbridge.com/en/news/289275111.md) - [Camp4 Therapeutics Earnings Review: Q4 Summary](https://longbridge.com/en/news/277987792.md)